ES3035041T3 - Compositions and methods for the delivery of therapeutics - Google Patents
Compositions and methods for the delivery of therapeuticsInfo
- Publication number
- ES3035041T3 ES3035041T3 ES17816189T ES17816189T ES3035041T3 ES 3035041 T3 ES3035041 T3 ES 3035041T3 ES 17816189 T ES17816189 T ES 17816189T ES 17816189 T ES17816189 T ES 17816189T ES 3035041 T3 ES3035041 T3 ES 3035041T3
- Authority
- ES
- Spain
- Prior art keywords
- acid
- prodrug
- hiv
- nanoparticle
- nanoparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662353736P | 2016-06-23 | 2016-06-23 | |
| PCT/US2017/038693 WO2017223280A2 (en) | 2016-06-23 | 2017-06-22 | Compositions and methods for the delivery of therapeutics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3035041T3 true ES3035041T3 (en) | 2025-08-27 |
Family
ID=60784694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17816189T Active ES3035041T3 (en) | 2016-06-23 | 2017-06-22 | Compositions and methods for the delivery of therapeutics |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11117904B2 (OSRAM) |
| EP (3) | EP4299133A3 (OSRAM) |
| JP (1) | JP7160466B2 (OSRAM) |
| ES (1) | ES3035041T3 (OSRAM) |
| WO (1) | WO2017223280A2 (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11839623B2 (en) | 2018-01-12 | 2023-12-12 | Board Of Regents Of The University Of Nebraska | Antiviral prodrugs and formulations thereof |
| US20200407393A1 (en) * | 2018-03-07 | 2020-12-31 | Glaxosmithkline Intellectual Property (No. 2) Limited | Medical Use |
| US11458136B2 (en) | 2018-04-09 | 2022-10-04 | Board Of Regents Of The University Of Nebraska | Antiviral prodrugs and formulations thereof |
| EP4234560A3 (en) * | 2018-10-22 | 2023-09-13 | Board of Regents of the University of Nebraska | Antiviral prodrugs and nanoformulations thereof |
| CN113382737B (zh) | 2018-11-29 | 2025-06-03 | 内布拉斯加大学董事会 | 抗病毒前药及其纳米制剂 |
| US20220096503A1 (en) * | 2019-01-11 | 2022-03-31 | University Of Washington | Combination pharmaceutical compositions and methods thereof |
| EP3934760A1 (en) | 2019-03-06 | 2022-01-12 | GlaxoSmithKline Intellectual Property (No.2) Limited | Compounds useful in hiv therapy |
| IL286328B1 (en) | 2019-03-22 | 2026-04-01 | Gilead Sciences Inc | Tricyclic bridging compounds of carbamoylpyridone and their pharmaceutical use |
| CA3164528A1 (en) * | 2019-12-09 | 2021-06-17 | Viiv Healthcare Company | Pharmaceutical compositions comprising cabotegravir |
| CR20220418A (es) | 2020-02-24 | 2022-10-10 | Gilead Sciences Inc | Compuestos tetracíclicos para el tratamiento de infecciones por vih |
| CA3192145A1 (en) | 2020-09-30 | 2022-04-07 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| JP7591155B2 (ja) | 2021-01-19 | 2024-11-27 | ギリアード サイエンシーズ, インコーポレイテッド | 置換ピリドトリアジン化合物及びその使用 |
| WO2023183472A1 (en) * | 2022-03-23 | 2023-09-28 | Board Of Regents Of The University Of Nebraska | Antiviral prodrugs and use thereof |
| TWI856796B (zh) | 2022-04-06 | 2024-09-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| EP4619400A4 (en) * | 2023-01-18 | 2026-03-25 | Ascletis Bioscience Co Ltd | Integrase inhibitor and its use |
| KR20260022300A (ko) * | 2023-04-26 | 2026-02-19 | 유니버시티 오브 워싱톤 | 인테그레이즈 가닥 전이 억제제의 장기 작용형 콜로이드형 약제학적 조성물 및 관련 방법 |
| WO2025011661A1 (zh) * | 2023-07-12 | 2025-01-16 | 歌礼生物科技(杭州)有限公司 | 整合酶抑制类的制剂及其制备方法 |
| WO2025128496A1 (en) | 2023-12-12 | 2025-06-19 | Viiv Healthcare Company | Crystalline form |
| WO2025128498A1 (en) | 2023-12-12 | 2025-06-19 | Viiv Healthcare Company | Pharmaceutical compositions |
| WO2026012272A1 (en) * | 2024-07-12 | 2026-01-15 | Ascletis Bioscience Co., Ltd. | Integrase inhibitor and use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1874117E (pt) | 2005-04-28 | 2013-10-17 | Shionogi & Co | Derivado policíclico de carbamoílpiridona possuindo actividade inibidora de hiv-integrasse |
| CN103951643B (zh) * | 2008-07-25 | 2015-12-09 | 盐野义制药株式会社 | 用作hiv整合酶抑制剂的化合物 |
| WO2010011815A1 (en) * | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| SI2320908T1 (sl) * | 2008-07-25 | 2014-05-30 | Viiv Healthcare Company | Predzdravila dolutegravirja |
| PT2602260T (pt) * | 2010-08-05 | 2016-12-27 | Shionogi & Co | Processo para preparar composto possuindo atividade inibidora de integrase do vih |
| TWI577377B (zh) * | 2010-09-16 | 2017-04-11 | Viiv醫療保健公司 | 醫藥組合物 |
| JP2013542945A (ja) | 2010-11-02 | 2013-11-28 | ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ | 治療を送達するための組成物および方法 |
| CA2893843C (en) * | 2012-12-21 | 2018-09-04 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| HK1214817A1 (en) | 2012-12-27 | 2016-08-05 | Japan Tobacco Inc. | Substituted spiropyrido[1,2-a]pyrazine derivative and medicinal use thereof as hiv integrase inhibitor |
| WO2015039348A1 (en) * | 2013-09-23 | 2015-03-26 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors |
| EP3110422A4 (en) * | 2014-02-24 | 2017-09-06 | Board of Regents of the University of Nebraska | Compositions and methods for the delivery of therapeutics |
-
2017
- 2017-06-22 ES ES17816189T patent/ES3035041T3/es active Active
- 2017-06-22 EP EP23208918.5A patent/EP4299133A3/en active Pending
- 2017-06-22 US US16/304,759 patent/US11117904B2/en active Active
- 2017-06-22 JP JP2018567638A patent/JP7160466B2/ja active Active
- 2017-06-22 EP EP17816189.9A patent/EP3474857B1/en active Active
- 2017-06-22 WO PCT/US2017/038693 patent/WO2017223280A2/en not_active Ceased
- 2017-06-22 EP EP25156350.8A patent/EP4527463A3/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7160466B2 (ja) | 2022-10-25 |
| WO2017223280A3 (en) | 2019-04-25 |
| US20210230186A1 (en) | 2021-07-29 |
| US11117904B2 (en) | 2021-09-14 |
| EP4299133A3 (en) | 2024-03-13 |
| EP3474857A2 (en) | 2019-05-01 |
| EP3474857A4 (en) | 2020-03-18 |
| EP3474857C0 (en) | 2025-05-21 |
| EP4527463A3 (en) | 2025-06-25 |
| EP4299133A2 (en) | 2024-01-03 |
| EP4527463A2 (en) | 2025-03-26 |
| JP2019524670A (ja) | 2019-09-05 |
| EP3474857B1 (en) | 2025-05-21 |
| WO2017223280A2 (en) | 2017-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3474857B1 (en) | Compositions and methods for the delivery of therapeutics | |
| US20220211714A1 (en) | Compositions and methods for the delivery of therapeutics | |
| ES2970251T3 (es) | Profármacos antivirales y nanoformulaciones de los mismos | |
| US12257306B2 (en) | Antiviral prodrugs and nanoformulations thereof | |
| US11839623B2 (en) | Antiviral prodrugs and formulations thereof | |
| US20170165271A1 (en) | Compositions and Methods for the Delivery of Therapeutics | |
| US20220288037A1 (en) | Prodrugs and formulations thereof | |
| US20160136105A1 (en) | Compositions and Methods for the Delivery of Therapeutics | |
| US11458136B2 (en) | Antiviral prodrugs and formulations thereof | |
| US20180028457A1 (en) | Compositions and Methods for the Delivery of Therapeutics | |
| BR122024017400A2 (pt) | Compostos antivirais, nanopartícula, composição farmacêutica e uso |